IL138604A0 - Inflammatory mediator antagonists - Google Patents

Inflammatory mediator antagonists

Info

Publication number
IL138604A0
IL138604A0 IL13860499A IL13860499A IL138604A0 IL 138604 A0 IL138604 A0 IL 138604A0 IL 13860499 A IL13860499 A IL 13860499A IL 13860499 A IL13860499 A IL 13860499A IL 138604 A0 IL138604 A0 IL 138604A0
Authority
IL
Israel
Prior art keywords
antagonists
inflammatory mediator
mediator antagonists
osm
inflammatory
Prior art date
Application number
IL13860499A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of IL138604A0 publication Critical patent/IL138604A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
IL13860499A 1998-03-26 1999-03-25 Inflammatory mediator antagonists IL138604A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9806530.3A GB9806530D0 (en) 1998-03-26 1998-03-26 Inflammatory mediator
PCT/GB1999/000943 WO1999048523A2 (en) 1998-03-26 1999-03-25 Antagonists of the inflammatory mediator oncostatin m (osm)

Publications (1)

Publication Number Publication Date
IL138604A0 true IL138604A0 (en) 2001-10-31

Family

ID=10829337

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13860499A IL138604A0 (en) 1998-03-26 1999-03-25 Inflammatory mediator antagonists

Country Status (20)

Country Link
US (5) US6706266B1 (xx)
EP (2) EP1849478A3 (xx)
JP (2) JP3825255B2 (xx)
KR (1) KR20010034672A (xx)
CN (1) CN1295482A (xx)
AT (1) ATE338565T1 (xx)
AU (1) AU3046399A (xx)
BR (1) BR9909077A (xx)
CA (1) CA2325585A1 (xx)
CY (1) CY1105722T1 (xx)
DE (1) DE69933115T2 (xx)
DK (1) DK1071449T3 (xx)
ES (1) ES2272058T3 (xx)
GB (1) GB9806530D0 (xx)
HU (1) HUP0101690A2 (xx)
IL (1) IL138604A0 (xx)
PL (1) PL343431A1 (xx)
PT (1) PT1071449E (xx)
WO (1) WO1999048523A2 (xx)
ZA (1) ZA200005076B (xx)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9806530D0 (en) * 1998-03-26 1998-05-27 Glaxo Group Ltd Inflammatory mediator
WO2001081345A1 (fr) * 2000-04-20 2001-11-01 Mitsubishi Pharma Corporation Composes d'amides aromatiques
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
WO2003035048A2 (en) * 2001-10-26 2003-05-01 Novartis Ag Methods for the treatment of osteoarthritis and compositions thereof
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
EP1581169A4 (en) * 2002-11-08 2008-09-17 Genentech Inc COMPOSITIONS AND METHODS FOR TREATING DISEASES RELATED TO NATURAL K CELLS
JP4803789B2 (ja) * 2004-02-03 2011-10-26 独立行政法人科学技術振興機構 疼痛を処置するための薬学的組成物
CA2562953A1 (en) * 2004-03-30 2005-10-13 Glaxo Group Limited Humanized and chimeric anti-osm antibodies
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
EP1795204A4 (en) * 2004-09-29 2009-10-21 Asama Kasei Kk FUNCTIONAL COMPOSITION OR FOODS WITH MOLKEPROTEIN, FROM MILK-ORGANIC ANTIBODIES OR ANTIBODIES
US10080779B2 (en) 2004-12-15 2018-09-25 Universite D'angers Method for increasing the expression of anti-microbial peptides by keratinocytes comprising administering a composition comprising IL-17, TNF-alpha and OSM
EP1671642A1 (en) * 2004-12-15 2006-06-21 Universite D'angers Compositions comprising (ant)agonists of oncostatin M (OSM), IL-31 and IFN-gamma for modulating keratinocyte migration and functions via a receptor containing OSMRbeta as a subunit, and applications thereof.
US20060276440A1 (en) * 2005-01-03 2006-12-07 An Wenqian F Treatment of inflammatory disorders
EP1877556B1 (en) * 2005-03-25 2011-09-14 Medtronic, Inc. Use of anti-tnf or anti-il1 rnai to suppress pro- inflammatory cytokine actions locally to treat pain
EP1915436B1 (en) * 2005-08-02 2011-09-28 Trustees Of Tufts College Methods for stepwise deposition of silk fibroin coatings
WO2008134077A1 (en) * 2007-04-30 2008-11-06 Archemix Corp. Metabolic profile directed aptamer medicinal chemistry
JP2010532790A (ja) * 2007-07-06 2010-10-14 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 抗体処方
US8030290B2 (en) 2007-12-07 2011-10-04 City Of Hope Cell-type specific aptamer-siRNA delivery system for HIV-1 Therapy
USRE48948E1 (en) 2008-04-18 2022-03-01 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
AR074777A1 (es) 2008-12-19 2011-02-09 Glaxo Group Ltd Proteinas de union a antigeno
US8309688B2 (en) * 2008-12-30 2012-11-13 Centocor Ortho Biotech Inc. Monkey homolog of human oncostatin M and methods of use thereof
EP2401297A1 (en) * 2009-02-24 2012-01-04 Glaxo Group Limited Antigen-binding constructs
US20100239632A1 (en) 2009-03-23 2010-09-23 Warsaw Orthopedic, Inc. Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue
WO2011080050A2 (en) 2009-12-11 2011-07-07 Novartis Ag Binding molecules
WO2011094259A2 (en) 2010-01-28 2011-08-04 Glaxo Group Limited Cd127 binding proteins
UA108227C2 (xx) 2010-03-03 2015-04-10 Антигензв'язуючий білок
AR081556A1 (es) 2010-06-03 2012-10-03 Glaxo Group Ltd Proteinas de union al antigeno humanizadas
ES2717908T3 (es) 2010-06-14 2019-06-26 Lykera Biomed S A Anticuerpos S100A4 y usos terapéuticos de los mismos
EA031044B1 (ru) * 2010-10-13 2018-11-30 Янссен Байотек, Инк. Человеческие антитела к онкостатину м и способы их применения
KR20210021109A (ko) 2010-11-08 2021-02-24 제넨테크, 인크. 피하 투여용 항―ｉｌ―6 수용체 항체
WO2012069433A2 (en) * 2010-11-23 2012-05-31 Glaxo Group Limited Antigen binding proteins
WO2013168829A1 (en) 2012-05-11 2013-11-14 Wakayama Medical University Anti oncostatin m receptor beta antibody
US9663571B2 (en) 2013-05-30 2017-05-30 Kiniksa Pharmaceuticals, Ltd. Oncostatin M receptor antigen binding proteins
US10307487B2 (en) * 2013-07-09 2019-06-04 President And Fellows Of Harvard College Microvessel endothelial cell surface markers and uses thereof
US9550828B2 (en) * 2013-09-05 2017-01-24 Boise State University Oncostatin M (OSM) antagonists for preventing cancer metastasis and IL-6 related disorders
JP2014062100A (ja) * 2013-11-05 2014-04-10 Glaxosmithkline Llc 抗体処方
EP3069137A1 (en) 2013-11-05 2016-09-21 Novartis Ag Organic compounds
CN104096219A (zh) * 2014-07-08 2014-10-15 武汉大学 Ⅱ型抑瘤素m受体（osmr）在治疗脂肪肝和ⅱ型糖尿病中的功能和应用
EP2985294A1 (en) 2014-08-14 2016-02-17 Deutsches Krebsforschungszentrum Recombinant antibody molecule and its use for target cell restricted T cell activation
WO2016046738A1 (en) 2014-09-24 2016-03-31 Università Degli Studi Di Padova Composition to induce bone marrow stem cell mobilization
WO2016059602A2 (en) 2014-10-16 2016-04-21 Glaxo Group Limited Methods of treating cancer and related compositions
WO2016120625A1 (en) * 2015-01-29 2016-08-04 Isis Innovation Limited Biomarker
GB201614627D0 (en) * 2016-08-30 2016-10-12 Glaxosmithkline Ip Dev Ltd Antigen binding proteins
US11633457B2 (en) 2019-04-11 2023-04-25 Boise State University Pharmaceutical compositions comprising oncostatin m (OSM) antagonist derivatives and methods of use

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US646727A (en) * 1899-06-20 1900-04-03 Columbia Motor And Mfg Company Steam-generator.
US5618715A (en) * 1985-12-20 1997-04-08 Oncogen Limited Partnership Oncostatin M and novel compositions having anti-neoplastic activity
US5681930A (en) * 1985-12-20 1997-10-28 Bristol-Myers Squibb Company Anti-oncostatin M monoclonal antibodies
JPS6463395A (en) 1987-05-04 1989-03-09 Oncogen Oncostatin m and novel composition having antitumor activity
US5814307A (en) 1989-04-10 1998-09-29 Bristol-Myers Squibb Company Method for regulating cell growth, leukocyte differentiation and tumor cell growth using Oncostatin M to stimulate synthesis of IL-6
DK0422186T3 (da) 1989-04-10 1999-08-16 Oncogen Anvendelse af oncostatin M til suppression af MHC-antigener
AU651330B2 (en) 1989-12-08 1994-07-21 Oncogen Limited Partnership Novel proteins with oncostatin M activity and process for their preparation
NZ237533A (en) * 1990-03-29 1992-12-23 Bristol Myers Squibb Co Monoclonal antibodies which bind to oncostatin m, cell lines producing them
DE4011684A1 (de) 1990-04-06 1991-10-10 Schering Ag Dtpa-monoamide, diese verbindungen enthaltende pharmazeutische mittel, ihre verwendung und verfahren zu deren herstellung
CA2055122A1 (en) 1990-11-13 1992-05-14 Robert I. Grove Methods for stimulating ldl uptake and ldl receptor expression
AU666866B2 (en) 1991-08-30 1996-02-29 Fred Hutchinson Cancer Research Center Hybrid cytokines
US6171824B1 (en) 1991-08-30 2001-01-09 Fred Hutchinson Cancer Research Center Hybrid cytokines
US5262522A (en) * 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
JPH05304986A (ja) 1992-04-28 1993-11-19 Tosoh Corp ｇｐ１３０蛋白質に対するモノクロ−ナル抗体
US5744442A (en) 1992-08-26 1998-04-28 Bristol Meyers Squibb Company Regulation of cellular invasiveness
US5460810A (en) 1992-09-02 1995-10-24 Genetics Institute, Inc. Method for maintaining gut epithelial cells by treatment with a cytokine such as interleukin 11
IT1261787B (it) 1993-06-23 1996-06-03 Angeletti P Ist Richerche Bio Metodologia per la selezione di superagonisti, antagonisti e super- antagonisti di ormoni del cui complesso recettoriale fa parte gp 130.
FR2707882B1 (fr) * 1993-07-23 1997-08-01 Immunotech Sa Nouveaux kits thérapeutiques anti-médiateurs protéiques, procédé de préparation et compositions pharmaceutiques les renfermant.
US5451411A (en) * 1993-10-15 1995-09-19 University Of Washington Methods and compositions for the oral delivery of therapeutic agents
US5783672A (en) 1994-05-26 1998-07-21 Immunex Corporation Receptor for oncostatin M
GB9419021D0 (en) 1994-09-21 1994-11-09 Applied Research Systems Therapeutic protein
US5571513A (en) 1995-05-31 1996-11-05 The Board Of Regents Of The University Of Oklahoma Anti-gp130 monoclonal antibodies
JPH09117288A (ja) 1995-06-06 1997-05-06 Bristol Myers Squibb Co オンコスタチンｍ誘導造血
WO1997016202A1 (en) 1995-10-27 1997-05-09 Amrad Operations Pty. Ltd. Cytokines and their use in treatment and/or prophylaxis of breast cancer
WO1998018483A1 (en) 1996-10-25 1998-05-07 Bristol-Myers Squibb Company Oncostatin m for treating inflammation
US5958442A (en) * 1997-10-24 1999-09-28 Bristol-Myers Squibb Company Oncostatin M for treating inflammation
GB9806530D0 (en) * 1998-03-26 1998-05-27 Glaxo Group Ltd Inflammatory mediator

Also Published As

Publication number Publication date
PT1071449E (pt) 2006-12-29
DK1071449T3 (da) 2007-01-02
US8003101B2 (en) 2011-08-23
JP3825255B2 (ja) 2006-09-27
US20040081650A1 (en) 2004-04-29
ZA200005076B (en) 2001-09-21
JP2006290893A (ja) 2006-10-26
BR9909077A (pt) 2000-12-05
JP2002507580A (ja) 2002-03-12
WO1999048523A2 (en) 1999-09-30
US20080044409A1 (en) 2008-02-21
US20060093602A1 (en) 2006-05-04
KR20010034672A (ko) 2001-04-25
EP1849478A3 (en) 2013-05-29
GB9806530D0 (en) 1998-05-27
WO1999048523A3 (en) 1999-11-25
DE69933115D1 (de) 2006-10-19
CA2325585A1 (en) 1999-09-30
EP1071449B1 (en) 2006-09-06
AU3046399A (en) 1999-10-18
CY1105722T1 (el) 2010-12-22
US7291332B2 (en) 2007-11-06
PL343431A1 (en) 2001-08-13
ATE338565T1 (de) 2006-09-15
EP1071449A2 (en) 2001-01-31
US20080019967A1 (en) 2008-01-24
CN1295482A (zh) 2001-05-16
DE69933115T2 (de) 2007-04-05
EP1849478A2 (en) 2007-10-31
HUP0101690A2 (hu) 2001-08-28
ES2272058T3 (es) 2007-04-16
US6706266B1 (en) 2004-03-16

Similar Documents

Publication Publication Date Title
GB9806530D0 (en) Inflammatory mediator
CY1105386T1 (el) Βενζοϋλοσουλφοναμιδια και σουλφονυλβενζαμιδινες για χρηση σαν παραγοντες κατα του ογκου
EA200301073A1 (ru) N-(2-арилэтил)бензиламины в качестве антагонистов 5-ht-рецептора
EP1017713A4 (en) CYCLIC AGONISTS AND ANTAGONISTS OF THE C5A RECEPTORS AND G-PROTEIN COUPLED RECEPTORS
MY113806A (en) Antiparasitic marcfortines and paraherquamides
NO983431L (no) Anti-klöemidler
ES2176212T3 (es) Eteres de fosfonooximetilicos o metiltiometilicos de derivados de taxano como agentes antitumorales.
EA200300580A1 (ru) Соединения лактама
PT1671949E (pt) Piridinilaminas substituídas
EA200601555A1 (ru) Замещенные индазол-о-глюкозиды
IL149459A0 (en) Recombinant gelatins
ES2178676T3 (es) Compuestos de pirimidina substituidos y su empleo.
EA200400510A1 (ru) Агенты, специфически связывающие ангиопоэтин-2
EA200100773A1 (ru) Замещенные 1-гетероциклические диариламины
IS5769A (is) Taugasæknir thættir
PT842934E (pt) Agonistas de 5-ht1f
MX9805499A (es) Compuestos de azacicloheptano y diazacicloheptano y ciclooctano sustituidos y su uso.
EA200400582A1 (ru) Тиофен- и тиазолсульфонамиды в качестве противоопухолевых средств
ID26034A (id) Helai serat kaca yang dilapisi dengan pelumas anorganik
EA200100516A1 (ru) Производные 3,3-биарилпиперидина и 2,2-биарилморфолина
MY141607A (en) Lactam compound
EA200400670A1 (ru) Фармацевтические композиции, содержащие 3,4-пропинопергидропурины, и их применение для блокирования нейронной передачи
ATE232081T1 (de) Orale zusammensetzung enthaltend perlit
EA199700223A1 (ru) Бициклические антагонисты тахикининов, их получение и применение в фармацевтической композиции
TR200001080T2 (tr) 2 ile ikame edilmiş 1,2-Benisotiyazol türevleri ve bunların serrotonın antagonistleri